Latest news with #investorConferences
Yahoo
5 days ago
- Business
- Yahoo
Ribbon Joins Two Investor Conferences in June
PLANO, Texas, June 5, 2025 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a leading supplier of real-time communications technology and IP optical networking solutions, announced the investor conferences its executives will attend later this month: Rosenblatt 5th Annual Technology Virtual Summit Tech Conference, June 10, 2025 Northland Capital Virtual Growth Conference, June 25, 2025 Qualified participants may email ir@ to set up virtual meetings with Ribbon leadership. Ribbon is dedicated to assisting the world's largest service providers, enterprises and critical infrastructure operators in modernizing and safeguarding their networks and services. About RibbonRibbon Communications (Nasdaq: RBBN) delivers secure cloud communications and IP and optical networking solutions to service providers, enterprises and critical infrastructure sectors globally. We engage deeply with our customers, helping them modernize their networks for improved competitive positioning and business outcomes in today's smart, always-on and data-hungry world. Our end-to-end portfolio of communications software and IP Optical networking solutions delivers superior value and innovation by leveraging cloud-native architectures, automation and analytics tools, and leading-edge security. We maintain a keen focus on our commitments to Environmental, Social, and Governance (ESG) matters, offering an annual Sustainability Report to our stakeholders. To learn more about Ribbon, please visit Important Information Regarding Forward-Looking StatementsThe information in this release contains forward-looking statements regarding future events that involve risks and uncertainties. All statements other than statements of historical facts contained in this release, including those regarding the expected benefits from use of Ribbon Communication's products, are forward-looking statements. The actual results of Ribbon Communications may differ materially from those contemplated by the forward-looking statements. For further information regarding risks and uncertainties associated with Ribbon Communications' business, please refer to the "Risk Factors" section of Ribbon Communications' most recent annual or quarterly report filed with the SEC. Any forward-looking statements represent Ribbon Communications' views only as of the date on which such statement is made and should not be relied upon as representing Ribbon Communications' views as of any subsequent date. While Ribbon Communications may elect to update forward-looking statements at some point, Ribbon Communications specifically disclaims any obligation to do so. Investor Contact+1 (978) 614-8050ir@ Media ContactCatherine Berthier+1 (646) 741-1974cberthier@ View original content to download multimedia: SOURCE Ribbon Communications Inc. Sign in to access your portfolio
Globe and Mail
27-05-2025
- Business
- Globe and Mail
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ET Goldman Sachs 46th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 10, 2025, at 10:00 a.m. ET Webcasts of the discussions will be available through the investor section of the company's website at Replays of the webcasts will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC ® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn.
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New York Fireside Chat June 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New York Panelist: ' Dermatology: AA, HS, PSO' June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit About AVTX-009 AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. For media and investor inquiries Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@ 410-803-6793 or Meru Advisors Lauren Glaser
Associated Press
27-05-2025
- Business
- Associated Press
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New York Fireside Chat June 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New York Panelist: ' Dermatology: AA, HS, PSO' June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under 'News / Events' in the Investors section of the Avalo Therapeutics website at The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit About AVTX-009 AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. For media and investor inquiries Christopher Sullivan, CFO Avalo Therapeutics, Inc. [email protected] 410-803-6793 or Meru Advisors Lauren Glaser [email protected]
